(CercleFinance.com) – Novartis on Wednesday expressed its intention to rigorously assert its rights following an unfavorable court decision in the United States concerning the patent for the immunosuppressant Gilenya.
The Swiss biopharmaceutical group indicates that the Court of Appeals for the Federal Circuit (CAFC) has rendered a negative opinion on the validity of a certain dosage regimen of its drug, used in the treatment of multiple sclerosis.
Novartis recalls that in August 2020, a Delaware court ruled in its favor against HEC Pharma by extending its patent on Gilenya until the end of 2027.
HEC Pharma challenged this decision, which was first confirmed by the CAFC in early 2022, before being reversed yesterday.
In its press release, Novartis said it was considering all the options available to it, including the possibility of a full appeal to the court of appeal, a process that could last for many months.
The laboratory recalls that it had previously agreed with a certain number of generic manufacturers in order to guard against the arrival of biosimilar versions of Gilenya before a certain date.
On the Zurich Stock Exchange, Novartis shares fell more than 0.5% on Wednesday morning following these announcements.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
–
